Literature DB >> 31737511

First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?

Paul Hofman1,2,3.   

Abstract

Entities:  

Year:  2019        PMID： 31737511      PMCID： PMC6835100          DOI： 10.21037/tlcr.2019.04.18

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  14 in total

1.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Kristel Vandormael; Antonio Riccio; Jing Yang; M Catherine Pietanza; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2019-01-08       Impact factor: 44.544

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

Review 3.  Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?

Authors:  Simon Heeke; Paul Hofman
Journal:  Transl Lung Cancer Res       Date:  2018-12

4.  Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray.

Authors:  Hedvig Elfving; Johanna Sofia Margareta Mattsson; Cecilia Lindskog; Max Backman; Uwe Menzel; Patrick Micke
Journal:  Clin Lung Cancer       Date:  2019-02-27       Impact factor: 4.785

5.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.

Authors:  M Ilie; E Long-Mira; C Bence; C Butori; S Lassalle; L Bouhlel; L Fazzalari; K Zahaf; S Lalvée; K Washetine; J Mouroux; N Vénissac; M Poudenx; J Otto; J C Sabourin; C H Marquette; V Hofman; P Hofman
Journal:  Ann Oncol       Date:  2015-10-19       Impact factor: 32.976

6.  PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.

Authors:  Mark Yarchoan; Lee A Albacker; Alexander C Hopkins; Meagan Montesion; Karthikeyan Murugesan; Teena T Vithayathil; Neeha Zaidi; Nilofer S Azad; Daniel A Laheru; Garrett M Frampton; Elizabeth M Jaffee
Journal:  JCI Insight       Date:  2019-03-21

7.  Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them.

Authors:  Marius Ilie; Paul Hofman
Journal:  Transl Lung Cancer Res       Date:  2017-12

8.  PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.

Authors:  Elena Vigliar; Umberto Malapelle; Antonino Iaccarino; Gennaro Acanfora; Pasquale Pisapia; Eduardo Clery; Caterina De Luca; Claudio Bellevicine; Giancarlo Troncone
Journal:  J Clin Pathol       Date:  2019-03-07       Impact factor: 3.411

9.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

10.  The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.

Authors:  Yaxiong Zhang; Lianpeng Chang; Yunpeng Yang; Wenfeng Fang; Yanfang Guan; Aiwei Wu; Shaodong Hong; Huaqiang Zhou; Gang Chen; Xi Chen; Shen Zhao; Qiufan Zheng; Hui Pan; Lanjun Zhang; Hao Long; Haoxian Yang; Xin Wang; Zhesheng Wen; Junye Wang; Hong Yang; Xuefeng Xia; Yuanyuan Zhao; Xue Hou; Yuxiang Ma; Ting Zhou; Zhonghan Zhang; Jianhua Zhan; Yan Huang; Hongyun Zhao; Ningning Zhou; Xin Yi; Li Zhang
Journal:  J Immunother Cancer       Date:  2019-04-03       Impact factor: 13.751
View more
  2 in total

Review 1.  Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.

Authors:  Risa L Wong; Evan Y Yu
Journal:  Curr Treat Options Oncol       Date:  2021-01-12

2.  Identifying optimal candidates for primary tumor resection among metastatic non-small cell lung cancer patients: a population-based predictive model.

Authors:  Hengrui Liang; Zhichao Liu; Jun Huang; Jun Liu; Wei Wang; Jianfu Li; Shan Xiong; Caichen Li; Bo Cheng; Yi Zhao; Fei Cui; Jianxing He; Wenhua Liang
Journal:  Transl Lung Cancer Res       Date:  2021-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.